In the initial phase 1 study [KEYNOTE-023] of pembrolizumab (another anti-PD-1 MoAb) and lenalidomide for relapsed MM, there was an overall response rate of 44% with an additional 50% of patients achieving stable disease; the 1-year survival rate was 82.6% (52). This evidence concerns the gene PDCD1 and Miyoshi myopathy.